Table 5.
Detection rate (DR) and area under receiver‐operating‐characteristics curve (AUC) for prediction of pre‐eclampsia before 37 weeks' gestation by Fetal Medicine Foundation competing‐risks model, according to whether pregnancy‐associated plasma protein‐A (PAPP‐A) and placental growth factor (PlGF) were measured before or after 11 weeks
| 8 + 0 to 10 + 6 weeks (n = 16) | 11 + 0 to 13 + 6 weeks (n = 14) | ||||||
|---|---|---|---|---|---|---|---|
| DR (% (95% CI)) at: | DR (% (95% CI)) at: | ||||||
| Method of screening | AUC (95% CI) | 5% FPR | 10% FPR | AUC (95% CI) | 5% FPR | 10% FPR | P * |
| A‐priori risk plus: | |||||||
| MAP | 0.722 (0.604–0.840) | 31.3 (12.5–56.3) | 31.3 (12.5–56.3) | 0.734 (0.593–0.875) | 21.4 (0–42.9) | 28.6 (7.1–50.0) | 0.910 |
| UtA‐PI | 0.749 (0.617–0.882) | 18.8 (0–37.7) | 43.8 (25.0–68.8) | 0.721 (0.566–0.876) | 21.4 (0–42.9) | 50.0 (28.4–78.6) | 0.791 |
| PAPP‐A | 0.689 (0.529–0.850) | 12.5 (0–37.5) | 31.3 (12.5–56.3) | 0.722 (0.592–0.853) | 21.4 (0–42.9) | 35.7 (14.3–57.1) | 0.759 |
| PlGF | 0.738 (0.633–0.842) | 12.5 (0–37.5) | 31.3 (12.5–56.3) | 0.737 (0.593–0.880) | 35.7 (14.3–57.1) | 35.7 (14.3–57.1) | 0.992 |
| PlGF + UtA‐PI | 0.746 (0.637–0.855) | 18.8 (0–43.8) | 37.5 (18.8–62.5) | 0.745 (0.603–0.886) | 42.9 (21.4–71.4) | 50.0 (21.4–78.6) | 0.992 |
| MAP + PlGF | 0.785 (0.700–0.869) | 31.3 (6.3–50.0) | 37.5 (18.8–62.5) | 0.797 (0.659–0.936) | 35.7 (14.3–64.3) | 42.9 (21.4–71.4) | 0.904 |
| MAP + UtA‐PI | 0.803 (0.721–0.885) | 25.0 (6.3–50.0) | 37.5 (18.8–62.5) | 0.766 (0.605–0.926) | 35.7 (14.3–64.3) | 50.0 (21.4–78.6) | 0.712 |
| PAPP‐A + PlGF | 0.746 (0.637–0.855) | 12.5 (0–43.8) | 43.8 (18.8–68.8) | 0.745 (0.603–0.886) | 35.7 (14.3–64.3) | 35.7 (14.3–64.3) | 0.992 |
| MAP + PAPP‐A | 0.741 (0.625–0.857) | 31.3 (6.3–56.3) | 43.8 (18.8–68.8) | 0.754 (0.612–0.896) | 14.3 (0–42.9) | 28.6 (7.1–57.1) | 0.901 |
| UtA‐PI + PAPP‐A | 0.767 (0.627–0.907) | 37.5 (12.5–68.8) | 56.3 (31.3–81.3) | 0.751 (0.610–0.892) | 28.6 (7.1–57.1) | 50.0 (29.9–78.6) | 0.877 |
| MAP + UtA‐PI + PAPP‐A | 0.815 (0.726–0.905) | 31.3 (12.5–56.3) | 43.8 (18.8–68.8) | 0.783 (0.624–0.942) | 35.7 (14.3–57.1) | 57.1 (28.6–85.7) | 0.744 |
| MAP + UtA‐PI + PlGF | 0.830 (0.760–0.899) | 18.8 (0–37.7) | 43.8 (18.8–68.8) | 0.804 (0.649–0.958) | 42.9 (14.3–71.4) | 57.1 (28.6–85.7) | 0.785 |
| MAP + PAPP‐A + PlGF | 0.793 (0.709–0.877) | 31.3 (12.5–56.3) | 43.8 (18.8–68.8) | 0.803 (0.665–0.942) | 35.7 (14.3–64.3) | 50.0 (21.4–78.6) | 0.919 |
| UtA‐PI + PlGF + PAPP‐A | 0.789 (0.683–0.894) | 25.0 (6.3–43.8) | 37.5 (12.5–62.5) | 0.764 (0.621–0.907) | 42.9 (14.3–71.4) | 50.0 (29.9–78.6) | 0.805 |
| MAP + UtA‐PI + PlGF + PAPP‐A | 0.818 (0.713–0.924) | 31.3 (6.3–50.0) | 50.0 (25.0–81.3) | 0.820 (0.669–0.971) | 42.9 (14.3–71.4) | 57.1 (28.6–85.7) | 0.983 |
*
Comparison between AUCs was by two‐tailed P‐value.
FPR, false‐positive rate; MAP, mean arterial pressure; UtA‐PI, uterine artery pulsatility index.